Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies

Figures

• 

  Fig. 1.. Boxplots of PAC (a) at baseline and Week 12 of PATENT-1 and (b) at baseline and Week 16 of CHEST-1. Each box shows the median and IQR, with the mean indicated by a cross. The vertical lines extend to 1.5 IQR, with outliers plotted separately. PAC was defined as stroke volume/(systolic pulmonary artery pressure – diastolic pulmonary artery pressure). An outlier of PAC 25.20 mL/mmHg was not included in (b) for improved visualization of the figure. PAC: pulmonary arterial compliance.

• 

  Fig. 2.. Mean PAC–PVR relationship (a) at baseline and Week 12 of PATENT-1 and (b) at baseline and Week 16 of CHEST-1. Data are mean ± standard error of the mean. PAC: pulmonary arterial compliance; PVR: pulmonary vascular resistance.

• 

  Fig. 3.. Change in PAC: in PATENT-1 and CHEST-1 for patients in low-, medium-, or high-risk REVEAL strata. Data are mean ± standard error of the mean. PAC: pulmonary arterial compliance. aData from Week 12 of PATENT-1 and Week 16 of CHEST-1.

• 

  Fig. 4.. Kaplan–Meier analysis for (a) survival and (b) clinical worsening-free survival in PATENT-2 and (c) survival and (d) clinical worsening-free survival in CHEST-2, separated by patients with PAC ≥ or < than the median at baseline. Log-rank tests were used to assess significance. For patients treated with riociguat in PATENT-1/CHEST-1, baseline was defined as PATENT-1/CHEST-1 baseline. For patients treated with placebo in PATENT-1/CHEST-1, baseline was defined as PATENT-1 Week 12/CHEST-1 Week 16 (the time immediately before the first riociguat dose). Day 0 was defined as the first day of the long-term extension phase in patients who received riociguat in PATENT-1 or CHEST-1, and as PATENT-2 or CHEST-2 Week 12 in patients who received placebo in PATENT-1 or CHEST-1 (after patients had received four weeks of therapy at their optimum riociguat dose). PAC: pulmonary arterial compliance.

• 

  Fig. 5.. Kaplan–Meier analysis for (a) survival and (b) clinical worsening-free survival in PATENT-2 and (c) survival and (d) clinical worsening-free survival in CHEST-2, separated by patients with PAC ≥ or < than the median at Week 12/16. Log-rank tests were used to assess significance. Only patients receiving riociguat (2.5 mg–maximum or 1.5 mg fixed dose) in PATENT-1 and CHEST-1 were included in this analysis. Day 0 was defined as the first day of the long-term extension phase. PAC: pulmonary arterial compliance.

• 

  Fig. 6.. Kaplan–Meier analysis for (a) survival and (b) clinical worsening-free survival in PATENT-2 and (c) survival and (d) clinical worsening-free survival in CHEST-2, separated by patients with a change in PAC from baseline to Week 12/16 ≥ or < than the median. Log-rank tests were used to assess significance. Only patients receiving riociguat (2.5 mg–maximum or 1.5 mg fixed dose) in PATENT-1 and CHEST-1 were included in this analysis. Day 0 was defined as the first day of the long-term extension phase. PAC: pulmonary arterial compliance.